Printer Friendly

Articles from M2 Pharma (July 19, 2018)

1-28 out of 28 article(s)
Title Author Type Words
Abbott reports Q2 2018 financial results. Financial report 150
Asceneuron SA passes US FDA's ODD for ASN120290 for treating progressive supranuclear palsy (PSP). 237
Bardy Diagnostics Raises Additional Growth Capital from Existing Investors. 283
Bioasis Seeks Non-Brokered Private Placement for Gross Proceeds of CDN 3m. 258
BioPorto announces FDA application submission for The NGAL Test. 245
Boehringer Ingelheim chooses to exercise exclusive license of human TCR-mimicking antibodies. 209
Bonesupport Holding names Michael Diefenbeck as head of Research & Development, Medical and Clinical Affairs. 140
Clinigen Group acquires Proleukin global rights outside US. 121
EvergreenHealth Names Amy E. Beiter, MD, as CEO. 328
eviCore healthcare announces St. Louis as its new service centre of healthcare providers. 157
FDA Grants Quidel Clearance for Diagnostic Assay for Identification of Pertussis, Parapertussis Infections. 197
Feinstein Institute researcher secures NIH USD3.5m to develop bladder cancer care programme. 270
Fusion Pharma Forms Advisory Board. 404
Invictus signs option agreement with OptionCo under the ACMPR. 257
Longevity Biotech Begins Study to Identify Inflammatory Biomarkers of Parkinson's Disease. 286
Novartis commits to immuno-dermatology with new license agreement. 195
Nuevolution reports exercise of opt-in right by Amgen in first programme from multiple target research collaboration. 353
Oxford BioDynamics awarded Canadian patent for EpiSwitch platform. 156
PainReform to conduct two pivotal Phase III clinical trials for post-operative pain relief after FDA approval. 157
PainReform wins US FDA's approval for Phase III post-operative pain relief study of PRF-110. 195
Pfizer Initiates Phase 3 Lead-in Study of Hemophilia B Gene Therapy. 354
RaySearch Laboratories awarded a major tender for its RayStation in Quebec, Canada. 254
RiMO Therapeutics Enrolls First Patient in Phase 1 Study of RiMO-301 With Radiation in Advanced Tumors. 158
Roche succeeds in phase three flu study of baloxavir marboxil. 297
Swedish Orphan Biovitrum's board exercises authorisation for repurchase of shares. 303
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets. 310
Theramex gains commercial license for Intrarosa in Europe, Australia, Russia and the Ukraine. 236
Xytex Opens New Location in Athens, Georgia. 169

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters